Drug Trial Radar · NCT03952039
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
Last checked: Nov 21, 2026Latest source record: Aug 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
202
Actual
Start
Sep 9, 2019
Primary completion
Dec 15, 2022
Study completion Jul 28, 2025
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
- First posted
- May 16, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy (BAT) in subjects with DIPSS (Dynamic International Prognostic Scoring System)-intermediate or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF) and previously treated with ruxolitinib. The primary objective of the study is to evaluate the percentage of subjects with at least 35% spleen volume reduction in the fedratinib and the BAT arms.
Conditions
- Primary Myelofibrosis
- Post-Polycythemia Vera
- Myelofibrosis
Interventions
FEDRATINIBDrug
A potent and selective inhibitor of JAK2 kinase activity
Best Available Therapy (BAT)Drug
Best available therapy (BAT)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Spleen Volume Response Rate (RR)Time frame: From Screening to end of Cycle 6 (1 cycle = 28 days), approximately 196 days
Locations
107 sites in 16 countries. Site status is shown where the registry gives one.
Local Institution - 100
Melbourne, Australia
Local Institution - 103
Darlinghurst, New South Wales, Australia
Local Institution - 101
Adelaide, South Australia, Australia
Local Institution - 105
Box Hill, Victoria, Australia
Local Institution - 102
Langwarrin, Victoria, Australia
Local Institution - 156
Graz, Austria
Local Institution - 154
Innsbruck, Austria
Local Institution - 155
Linz, Austria
Local Institution - 151
Salzburg, Austria
Local Institution - 150
Vienna, Austria
Local Institution - 152
Vienna, Austria
Local Institution - 153
Wels, Austria
Local Institution - 200
Bruges, Belgium
Local Institution - 202
Brussels, Belgium
Local Institution - 205
La Louvière-(Haine St-Paul), Belgium
Local Institution - 201
Leuven, Belgium
Local Institution - 204
Liège, Belgium
Local Institution - 203
Yvoir, Belgium
Local Institution - 555
Beijing, China
Local Institution - 550
Guangzhou, Guangdong, China
Local Institution - 553
Tianjin, China
Local Institution - 557
Zhengzhou, China
Local Institution - 700
Brno, Czechia
Local Institution - 702
Ostrava-Poruba, Czechia
Local Institution - 701
Prague, Czechia
Local Institution - 255
Angers, France
Local Institution - 256
Brest, France
Local Institution - 254
Lens, France
Local Institution - 259
Lille, France
Local Institution - 260
Nice, France
Local Institution - 250
Nîmes, France
Local Institution - 252
Paris, France
Local Institution - 258
Pessac, France
Local Institution - 257
Pierre-Bénite, France
Local Institution - 261
Poitiers, France
Local Institution - 251
Strasbourg, France
Local Institution - 253
Toulouse, France
Local Institution - 302
Aachen, Germany
Local Institution - 308
Frankfurt am Main, Germany
Local Institution - 306
Halle, Germany
Showing 40 of 107 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.